

## Evidence-Based Addiction Treatment

1. Nosyk, Bohdan, et al. "A call for evidence-based medical treatment of opioid dependence in the United States and Canada." *Health affairs* 32.8 (2013): 1462-1469.
2. Fairley, Michael, et al. "Cost-effectiveness of treatments for opioid use disorder." *JAMA psychiatry* 78.7 (2021): 767-777.
3. Heinrich, Carolyn J., and Grant R. Cummings. "Adoption and diffusion of evidence-based addiction medications in substance abuse treatment." *Health Services Research* 49.1 (2014): 127-152.
4. Wakeman, Sarah E., et al. "Comparative effectiveness of different treatment pathways for opioid use disorder." *JAMA network open* 3.2 (2020): e1920622-e1920622.
5. Thomas, Cindy Parks, et al. "Medication-assisted treatment with buprenorphine: assessing the evidence." *Psychiatric services* 65.2 (2014): 158-170.
6. Fullerton, Catherine Anne, et al. "Medication-assisted treatment with methadone: assessing the evidence." *Psychiatric services* 65.2 (2014): 146-157.
7. Hall, Martin T., et al. "Medication-assisted treatment improves child permanency outcomes for opioid-using families in the child welfare system." *Journal of Substance Abuse Treatment* 71 (2016): 63-67.
8. Jones, Christopher M., et al. "National and state treatment need and capacity for opioid agonist medication-assisted treatment." *American journal of public health* 105.8 (2015): e55-e63.
9. Maclean, Johanna Catherine, and Brendan Saloner. "The effect of public insurance expansions on substance use disorder treatment: evidence from the Affordable Care Act." *Journal of Policy Analysis and Management* 38.2 (2019): 366-393.
10. Meinhofer, Angélica, and Allison E. Witman. "The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion." *Journal of health economics* 60 (2018): 177-197.
11. Andrews, Christina M., et al. "Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs." *Medical Care Research and Review* 71.1 (2014): 43-60.

12. Schwartz, Robert P., et al. "Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009." *American journal of public health* 103.5 (2013): 917-922.
13. Knudsen, Hannah K., Lori J. Ducharme, and Paul M. Roman. "Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors." *Journal of substance abuse treatment* 30.4 (2006): 363-373.
14. Molfenter, Todd, et al. "Payer policy behavior towards opioid pharmacotherapy treatment in Ohio." *Journal of addiction medicine* 12.2 (2018): 85.
15. Stein, Bradley D., et al. "Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties." *The Milbank Quarterly* 93.3 (2015): 561-583.
16. Molfenter, Todd, et al. "Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio." *Substance abuse treatment, prevention, and policy* 10 (2015): 1-10.

### **Recovery Support**

1. Tracy, Kathlene, and Samantha P. Wallace. "Benefits of peer support groups in the treatment of addiction." *Substance abuse and rehabilitation* (2016): 143-154.
2. Magidson, Jessica F., et al. "Peer recovery coaches in general medical settings: changes in utilization, treatment engagement, and opioid use." *Journal of Substance Abuse Treatment* 122 (2021): 108248.
3. Cos, Travis A., et al. "Do peer recovery specialists improve outcomes for individuals with substance use disorder in an integrative primary care setting? A program evaluation." *Journal of Clinical Psychology in Medical Settings* 27 (2020): 704-715.
4. Heo, Moonseong, et al. "Harm reduction and recovery services support (HRRSS) to mitigate the opioid overdose epidemic in a rural community." *Substance Abuse Treatment, Prevention, and Policy* 18.1 (2023): 23.
5. Waye, Katherine M., et al. "Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches." *Addictive behaviors* 89 (2019): 85-91.
6. Langabeer, James, et al. "Outreach to people who survive opioid overdose: Linkage and retention in treatment." *Journal of Substance Abuse Treatment* 111 (2020): 11-15.

7. Reif, Sharon, et al. "Recovery housing: Assessing the evidence." *Psychiatric Services* 65.3 (2014): 295-300.
8. Polcin, Douglas L., et al. "Sober living houses for alcohol and drug dependence: 18-month outcomes." *Journal of substance abuse treatment* 38.4 (2010): 356-365.
9. Milby, Jesse B., et al. "To house or not to house: The effects of providing housing to homeless substance abusers in treatment." *American journal of public health* 95.7 (2005): 1259-1265.
10. Jones, Hendree E., et al. "Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers." *Drug and Alcohol Dependence* 79.2 (2005): 119-128.
11. Priest, Kelsey C., and Dennis McCarty. "The role of the hospital in the 21st century opioid overdose epidemic: the addiction medicine consult service." *Journal of addiction medicine* 13.2 (2019): 104.

### **Post-Overdose Response**

1. Bailey, Amelia, Calla Harrington, and Elizabeth A. Evans. "A scoping review of community-based post-opioid overdose intervention programs: implications of program structure and outcomes." *Health & Justice* 11.1 (2023): 3.
2. Bagley, Sarah M., et al. "A scoping review of post opioid-overdose interventions." *Preventive Medicine* 128 (2019): 105813.
3. Clark, Angela K., Christine M. Wilder, and Erin L. Winstanley. "A systematic review of community opioid overdose prevention and naloxone distribution programs." *Journal of addiction medicine* 8.3 (2014): 153-163.
4. Donnelly, Ellen A., et al. "Addressing opioid misuse: Hero Help as a recovery and behavioural health response." *Journal of Community Safety and Well-Being* 6.3 (2021): 142-147.
5. Xuan, Ziming, et al. "Association of Implementation of Postoverdose Outreach Programs With Subsequent Opioid Overdose Deaths Among Massachusetts Municipalities." *JAMA psychiatry* 80.5 (2023): 468-477.
6. Kimmel, Simeon D., et al. "Characteristics of post-overdose outreach programs and municipal-level opioid overdose in Massachusetts." *International Journal of Drug Policy* 120 (2023): 104164.

7. Hecht, Michael L., et al. "Developing the Opioid Rapid Response System™ for Lay Citizen Response to the Opioid Overdose Crisis: a Randomized Controlled Trial." *Prevention Science* 24.7 (2023): 1386-1397.
8. Stephenson, Audrey, et al. "Educational training to improve opioid overdose response among health center staff: a quality improvement initiative." *Harm Reduction Journal* 20.1 (2023): 83.
9. Champagne-Langabeer, Tiffany, et al. "Emergency medical services targeting opioid user disorder: An exploration of current out-of-hospital post-overdose interventions." *Journal of the American College of Emergency Physicians Open* 1.6 (2020): 1230-1239.
10. Donnelly, Ellen A., et al. "Law enforcement-based outreach and treatment referral as a response to opioid misuse: assessing reductions in overdoses and costs." *Police Quarterly* 26.4 (2023): 441-465.
11. Formica, Scott W., et al. "Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts." *International Journal of Drug Policy* 54 (2018): 43-50.
12. Formica, Scott W., et al. "Practice Full Report: The Massachusetts Department of Public Health Post Overdose Support Team Initiative: A Public Health–Centered Co-Response Model for Post–Overdose Outreach." *Journal of Public Health Management and Practice* 28.6 (2022): S311.

### **Criminal Justice Diversion Programs**

1. Grella, Christine E., et al. "A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system." *International Journal of Drug Policy* 81 (2020): 102768.
2. Westerberg, Verner S., et al. "Community-based methadone maintenance in a large detention center is associated with decreases in inmate recidivism." *Journal of substance abuse treatment* 70 (2016): 1-6.
3. Evans, Elizabeth A., et al. "Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder." *Addiction* 114.8 (2019): 1396-1404.
4. Marsden, John, et al. "Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England." *Addiction* 112.8 (2017): 1408-1418.

5. Moore, Kelly E., et al. "Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review." *Journal of substance abuse treatment* 99 (2019): 32-43.
6. Larney, Sarah, et al. "Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration." *Addiction* 107.2 (2012): 372-380.
7. Lee, Joshua D., et al. "Extended-release naltrexone to prevent opioid relapse in criminal justice offenders." *New England journal of medicine* 374.13 (2016): 1232-1242.
8. Bird, Sheila M., et al. "Impact of opioid substitution therapy for Scotland's prisoners on drug-related deaths soon after prisoner release." *Addiction* 110.10 (2015): 1617-1624.
9. Friedmann, Peter D., et al. "Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions." *Substance Abuse* 33.1 (2012): 9-18.
10. Matusow, Harlan, et al. "Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes." *Journal of substance abuse treatment* 44.5 (2013): 473-480.
11. Binswanger, Ingrid A., et al. "Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009." *Annals of internal medicine* 159.9 (2013): 592-600.
12. Pierce, Matthias, et al. "National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009." *Drug and alcohol dependence* 146 (2015): 17-23.
13. Krawczyk, Noa, et al. "Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine." *Health Affairs* 36.12 (2017): 2046-2053.
14. Malta, Monica, et al. "Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review." *PLoS medicine* 16.12 (2019): e1003002.
15. Green, Traci C., et al. "Post-incarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system." *JAMA psychiatry* 75.4 (2018): 405-407.

16. Mantha, Shivani, et al. "State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015." *Drug and alcohol dependence* 206 (2020): 107654.
17. Krebs, Emanuel, et al. "The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California." *Addiction* 112.5 (2017): 838-851.
18. Hedrich, Dagmar, et al. "The effectiveness of opioid maintenance treatment in prison settings: a systematic review." *Addiction* 107.3 (2012): 501-517.

### **Naloxone Distribution**

1. Behar, Emily, et al. "Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain." *Journal of general internal medicine* 32 (2017): 291-295.
2. McDonald, Rebecca, and John Strang. "Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria." *Addiction* 111.7 (2016): 1177-1187.
3. Sohn, Minji, et al. "Association of naloxone coprescription laws with naloxone prescription dispensing in the United States." *JAMA network open* 2.6 (2019): e196215-e196215.
4. Guadamuz, Jenny S., et al. "Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017." *JAMA network open* 2.6 (2019): e195388-e195388.
5. Hill, Lucas G., et al. "Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA." *Addiction* 116.6 (2021): 1505-1511.
6. Wheeler, Eliza, et al. "Community-based opioid overdose prevention programs providing naloxone—United States, 2010." *MMWR. Morbidity and mortality weekly report* 61.6 (2012): 101.
7. Coffin, Phillip O., and Sean D. Sullivan. "Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal." *Annals of internal medicine* 158.1 (2013): 1-9.
8. Williams, Anna V., John Strang, and John Marsden. "Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation." *Drug and alcohol dependence* 132.1-2 (2013): 383-386.

9. Green, Traci C., Robert Heimer, and Laretta E. Grau. "Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States." *Addiction* 103.6 (2008): 979-989.
10. Ray, Bradley R., et al. "EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana." *Addiction* 113.12 (2018): 2271-2279.
11. Spivey, Christina A., et al. "Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies." *Journal of the American Pharmacists Association* 60.5 (2020): 694-701.
12. McAuley, Andrew, Lorna Aucott, and Catriona Matheson. "Exploring the life-saving potential of naloxone: a systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users." *International Journal of Drug Policy* 26.12 (2015): 1183-1188.
13. Follman, Sarah, et al. "Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose." *JAMA network open* 2.5 (2019): e193209-e193209.
14. Coffin, Phillip O., et al. "Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain." *Annals of internal medicine* 165.4 (2016): 245-252.
15. Walley, Alexander Y., et al. "Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis." *Bmj* 346 (2013).
16. Enteen, Lauren, et al. "Overdose prevention and naloxone prescription for opioid users in San Francisco." *Journal of Urban Health* 87 (2010): 931-941.
17. Darracq, Michael A., et al. "Pharmacist dispensed naloxone: Knowledge, availability, participation and cost in selected California counties." *International Journal of Drug Policy* 71 (2019): 113-117.
18. Freeman, Patricia R., et al. "Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing." *Journal of the American Pharmacists Association* 57.2 (2017): S28-S33.

19. Meyerson, Beth Elaine, et al. "Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016." *Drug and alcohol dependence* 188 (2018): 187-192.
20. Sisson, Michelle L., et al. "Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use." *Drug and alcohol dependence* (2023): 110815.
21. Haggerty, Lauren C., and Sharon S. Gatewood. "Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone." *Journal of the American Pharmacists Association* 58.4 (2018): S73-S77.
22. Xu, Jing, et al. "State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies." *Drug and alcohol dependence* 189 (2018): 37-41. Xu, Jing, et al. "State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies." *Drug and alcohol dependence* 189 (2018): 37-41.
23. Guy Jr, Gery P., et al. "Trends in state-level pharmacy-based naloxone dispensing rates, 2012–2019." *American journal of preventive medicine* 61.6 (2021): e289-e295.
24. Wheeler, Eliza, et al. "Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014." *Morbidity and Mortality Weekly Report* 64.23 (2015): 631.
25. Acharya, Mahip, et al. "Cost-effectiveness of intranasal naloxone distribution to high-risk prescription opioid users." *Value in Health* 23.4 (2020): 451-460.
26. Langham, Sue, et al. "Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom." *Value in health* 21.4 (2018): 407-415.
27. Walley, Alexander Y., et al. "Opioid overdose prevention with intranasal naloxone among people who take methadone." *Journal of substance abuse treatment* 44.2 (2013): 241-247.
28. Cherrier, Nelda, et al. "Community Distribution of Naloxone: A Systematic Review of Economic Evaluations." *PharmacoEconomics-Open* 6.3 (2022): 329-342.
29. Green, Traci C., et al. "Orienting patients to greater opioid safety: models of community pharmacy-based naloxone." *Harm reduction journal* 12 (2015): 1-9.



30. Clark, Angela K., Christine M. Wilder, and Erin L. Winstanley. "A systematic review of community opioid overdose prevention and naloxone distribution programs." *Journal of addiction medicine* 8.3 (2014): 153-163.